Overview

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

Status:
NOT_YET_RECRUITING

Trial end date:
2033-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma

Phase:

PHASE1

Details

Lead Sponsor:

Vastra Gotaland Region

Treatments:

Interleukin-2
Melphalan